Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial

贝伐单抗 医学 结直肠癌 肿瘤科 化疗 随机对照试验 内科学 癌症
作者
Gianluca Masi,Lisa Salvatore,Luca Boni,Fotios Loupakis,Chiara Cremolini,Lorenzo Fornaro,Marta Schirripa,S. Cupini,C. Barbara,V. Safina,Cristina Granetto,Elena Fea,Lorenzo Antonuzzo,C. Boni,Giacomo Allegrini,S. Chiara,D. Amoroso,Andrea Bonetti,Alfredo Falcone
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:26 (4): 724-730 被引量:152
标识
DOI:10.1093/annonc/mdv012
摘要

The combination of bevacizumab with fluorouracil-based chemotherapy is a standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the efficacy of continuing or reintroducing bevacizumab in combination with second-line chemotherapy after progression to bevacizumab-based first-line therapy.In this phase III study, patients with mCRC treated with fluoropyrimidine-based first-line chemotherapy plus bevacizumab were randomized to receive in second-line mFOLFOX-6 or FOLFIRI (depending on first-line regimen) with or without bevacizumab. The primary end point was progression-free survival. To detect a hazard ratio (HR) for progression of 0.70 with an α and β error of 0.05 and 0.20, respectively, 262 patients were required.In consideration of the results of the ML18147 trial, the study was prematurely stopped. Between April 2008 and May 2012, a total of 185 patients were randomized. Bevacizumab-free interval was longer than 3 months in 43% of patients in chemotherapy alone arm and in 50% of patients in the bevacizumab arm. At a median follow-up of 45.3 months, the median progression-free survival was 5.0 months in the chemotherapy group and 6.8 months in the bevacizumab group [adjusted HR = 0.70; 95% confidence interval (CI) 0.52-0.95; stratified log-rank P = 0.010]. Subgroup analyses showed a consistent benefit in all subgroups analyzed and in particular in patients who had continued or reintroduced bevacizumab. An improved overall survival was also observed in the bevacizumab arm (adjusted HR = 0.77; 95% CI 0.56-1.06; stratified log-rank P = 0.043). Responses (RECIST 1.0) were similar in the chemotherapy and bevacizumab groups (17% and 21%; P = 0.573). Toxicity profile was consistent with previously reported data.This study demonstrates that the continuation or the reintroduction of bevacizumab with second-line chemotherapy beyond first progression improves the outcome and supports the use of this strategy in the treatment of mCRC. ClinicalTrials.gov number: NCT00720512.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
erhan7发布了新的文献求助10
1秒前
顾矜应助yoyo采纳,获得10
1秒前
111完成签到,获得积分10
2秒前
一一完成签到,获得积分10
2秒前
Joyj99完成签到,获得积分10
2秒前
一丁点可爱完成签到,获得积分10
3秒前
赘婿应助iii采纳,获得30
3秒前
yiersan发布了新的文献求助10
4秒前
谷谷完成签到,获得积分10
4秒前
量子星尘发布了新的文献求助30
4秒前
4秒前
感动的刚发布了新的文献求助10
5秒前
5秒前
金鑫鑫完成签到,获得积分10
5秒前
感动清炎完成签到,获得积分10
5秒前
Bio应助哈登采纳,获得30
5秒前
vander完成签到,获得积分10
6秒前
bjcyqz完成签到,获得积分10
6秒前
顾小白完成签到,获得积分10
6秒前
tcf完成签到,获得积分10
7秒前
张nmky发布了新的文献求助10
7秒前
霸气的老姆关注了科研通微信公众号
7秒前
7秒前
czxchase发布了新的文献求助30
8秒前
erhan7完成签到,获得积分10
8秒前
左手的左手是左手完成签到,获得积分10
8秒前
9秒前
9秒前
smottom应助zhu采纳,获得10
10秒前
Ava应助钮钴禄甄嬛采纳,获得10
10秒前
10秒前
hana完成签到,获得积分10
10秒前
lin050711发布了新的文献求助10
10秒前
Hong_Bin完成签到,获得积分10
10秒前
Hello应助机智雁凡采纳,获得10
11秒前
Burke完成签到 ,获得积分10
11秒前
11秒前
布鲁布鲁发布了新的文献求助10
11秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Social Research Methods (4th Edition) by Maggie Walter (2019) 2390
A new approach to the extrapolation of accelerated life test data 1000
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4009429
求助须知:如何正确求助?哪些是违规求助? 3549323
关于积分的说明 11301690
捐赠科研通 3283833
什么是DOI,文献DOI怎么找? 1810413
邀请新用户注册赠送积分活动 886275
科研通“疑难数据库(出版商)”最低求助积分说明 811301